Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS

Anatomie en Neurowetenschappen0 个研究点目标入组 75 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•To participate in the MRI part of the study:
•- Clinically definite Relapsing Remitting or Secondary Progressive Multiple sclerosis
•- Sufficient visual acuity and motor performance to perform the MRI task
•- Between 18 and 60 years of age;To participate in the PET-part of the study:
•- Minimum hemoglobin values of 8 g/dl for men and 7 g/dl for women

•For the MRI-part of the study:
•- MR contraindications
•- Neurological and/or psychiatric disorders (other than MS; e.g. depression, schizophrenia, alcohol or drug abuse)
•- For MS patients: the use of corticosteroids in the 4 weeks prior to inclusion. ;For the PET-part of the study:
•- benzodiazepine use or other drug use that affects the benzodiazepine site on the GABA receptor system (e.g. imidazopyridines, pyrazolopryimidines en cyclopyrrolones) 6 weeks or less before the start of the study.
•- The use of GHB (gamma-hydroxybutyrate)
•- In the case of pregnancy or breastfeeding
•- Insufficient haemoglobin value values as discussed in the inclusion criteria.
•- (a history of) significant cardiac disease
•- exposure to previous radiation leading to an annual cumulative dose of more than 10mSv

发起方

Anatomie en Neurowetenschappen